TELA Bio, Inc. (NASDAQ:TELA – Get Rating) saw a significant decline in short interest in the month of April. As of April 30th, there was short interest totalling 39,800 shares, a decline of 64.7% from the April 15th total of 112,700 shares. Based on an average daily volume of 53,300 shares, the short-interest ratio is […]
08.05.2023 - MALVERN, Pa., May 08, 2023 (GLOBE NEWSWIRE) - TELA Bio, Inc. ( TELA Bio ) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by .
Leader in innovative soft-tissue tissue reconstruction solutions sponsors event advocating for and mentoring women in surgeryMALVERN, Pa., May 09, 2023 TELA Bio, Inc. , a commercial-stage. | May 9, 2023
Item 1.01 Entry into a Material Definitive Agreement.
On April 18, 2023, TELA Bio, Inc. entered into an underwriting
agreement with Jefferies LLC, Piper Sandler & Co.
and Lake Street Capital. | April 20, 2023
TELA Bio (NASDAQ:TELA – Get Rating) and MiMedx Group (NASDAQ:MDXG – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability. Analyst Ratings This is a summary of recent recommendations […]